Alan Skarbnik (@ASkarbnik), MD, director of the lymphoma and CLL program, Novant Health (Charlotte, NC), and Aaron Goodman (@AaronGoodman33), MD, hematologist, University of California San Diego, join the show for a long-awaited debate: treating double-hit lymphoma with R-CHOP vs dose-adjusted (DA)-EPOCH-R. The conversation gets testy when the trio describe ... Show More
Jan 13
Episode 261: Rebooting Cancer Care With Doug Flora
Returning guest Doug Flora, MD, LSSBB, practicing oncologist and healthcare innovator, joins the show to discuss his new book Rebooting Cancer Care and his pragmatic vision for how artificial intelligence is reshaping oncology today. Dr. Flora explores how AI is already being lev ... Show More
40m 59s
Jan 6
Episode 260: TNBC Now and the Future With Greg Vidal
Chadi sits down with Gregory Vidal, MD, PhD, medical oncologist at the West Cancer Center, for a comprehensive, state-of-the-field discussion on triple-negative breast cancer (TNBC). Dr. Vidal walks listeners through how TNBC emerged as a diagnosis of exclusion, who is most commo ... Show More
34m 41s
Apr 2023
Episode 234: Amar Kishan, MD, on Neoadjuvant or Adjuvant Radiotherapy for Prostate Cancer
<p>In the first part of our Hollywood tour, Amar Kishan, MD,
joins us to discuss his recent meta-analysis published in the Journal of
Clinical Oncology on the effects of concurrent adjuvant sequencing versus
neoadjuvant concurrent sequencing. Dr. Kishan also gives an overview of ... Show More
20m 35s
Dec 2021
Knowledge and Practice Patterns Among Pulmonologists for Molecular Biomarker Testing in Advanced NSCLC
CHEST December 2021, Volume 160, Issue 6 Gerard A. Silvestri, MD, FCCP, and Adam H. Fox, MD, join CHEST Podcast Moderator Dominique Pepper, MD, to discuss the current knowledge and practice of pulmonologists regarding biomarker testing and targeted therapies in advanced non-small ... Show More
32m 8s
Jan 2024
What's New in Prostate Cancer, RCC, and mUC at GU24
<p>Drs. Neeraj Agarwal and Jeanny Aragon-Ching discuss several key abstracts to be presented at the 2024 ASCO GU Cancers Symposium, including sequencing versus upfront combination therapies for mCRPC in the BRCAAway study, updates on the CheckMate-9ER and CheckMate-214 trials in ... Show More
25m 10s
<p class="MsoNormal" style="text-align: justify;"><span class= "normaltextrun"><span style= "font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-ansi-language: EN-US; mso-f ... Show More
